Salute e Benessere
Systemic Lupus Erythematosus Market to Advance Upto Whopping USD 10 Billion by 2030 | DelveInsight
For further information on the market impact by therapies, download the Systemic Lupus Erythematosus sample @
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The pathogenesis of Systemic Lupus Erythematosus is complex, and the understanding of SLE pathogenesis is constantly evolving. A break in the tolerance in genetically susceptible individuals, on exposure to environmental factors, leads to the activation of autoimmunity.
As per the assessment of DelveInsight, the in the was found to be in 2020 which is expected to increase during the study period.
As per DelveInsight's estimates, the accounted for Systemic Lupus Erythematosus prevalent cases.
The report offers epidemiological analysis for the study period 2018-2030 in the 7MM segmented into
Keen to learn how Systemic Lupus Erythematosus Epidemiological Trends are going to appear in 2030 for the 7 MM, Download @
There is no complete cure for Systemic Lupus Erythematosus currently, but there are many treatments available to help particular symptoms. Systemic Lupus Erythematosus involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs. Systemic Lupus Erythematosus treatment includes and which are the first-line therapies for mild Systemic Lupus Erythematosus. In addition, and —such as and —are used for Systemic Lupus Erythematosus treatment with organ involvement. The current Systemic Lupus Erythematosus market possesses two approved products, and .
The dynamics of the Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several Systemic Lupus Erythematosus pipeline therapies such as (also known as IPP-201101), being developed by , is a 21-mer linear peptide fragment analog. ImmuPharma has completed the Phase III clinical trial for the treatment of SLE. Lupuzor demonstrated a superior response rate over placebo (61.5% vs 47.3%). ImmuPharma and signed exclusive license and development agreement for Lupuzor to fund a new which is expected to start by 2022. Avion Pharmaceuticals has the exclusive rights for the commercialization of Lupuzor in the US. ImmuPharma retains all the rights to commercialize Lupuzor outside the US. Apart from this, is developing, , is an investigational humanized monoclonal antibody that specifically recognizes and binds to blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. Biogen is conducting clinical trials for the treatment of patients receiving Active SLE receiving background nonbiologic lupus standard of care.
In addition, being developed by in partnership with . It is an investigational humanized anti-CD40L antibody fragment that acts by preventing the interaction between CD40L on T-cells with CD40 on antigen-presenting cells through interactions with its receptor-CD40. The drug failed to meet its primary endpoint in the Phase II trial. However, the company continued the development of dapirolizumab pegol. The product is currently being developed jointly by UCB and Biogen to treat SLE in a Phase III trial. The topline results are expected in the first-half of 2024.
Discover more about therapy set to grab substantial Systemic Lupus Erythematosus share @
To know about more pipeline therapies covered in the report, visit @
The expected launch of is the main factor responsible for an increase in the Systemic Lupus Erythematosus market size in the coming years, assisted by an Systemic Lupus Erythematosus prevalent population. Also, owing to the during the developmental stage by , and for efficient treatment options to be made available in the market will directly boost the Systemic Lupus Erythematosus market. The the disease is also considered an aspect driving the Systemic Lupus Erythematosus market growth.
On the other hand, factors such as a and the serve as setbacks for the Systemic Lupus Erythematosus market growth. The makes entering the SLE market challenging for the pharmaceutical key players. Also, in the Systemic Lupus Erythematosus pipeline, might also play as obstructions in the Systemic Lupus Erythematosus market in the future.
Know which therapy is expected to score the touchdown first @
Request for a Webex demo of the report
Get in touch with our Business executive @
DelveInsight's report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like and others.
DelveInsight's report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like , and others
DelveInsight's report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like and several others.
DelveInsight's report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like and others.
DelveInsight's, report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, and others.
DelveInsight's, report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including , and several others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+1(918)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg